Tabuk Pharmaceuticals
Riyadh, Saudi Arabia· Est.
Leading MENA generic drug maker expanding into specialty oncology through strategic partnerships.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Leading MENA generic drug maker expanding into specialty oncology through strategic partnerships.
Anti‑infectivesBone ManagementCardiovascularCentral Nervous SystemDermatologyDiabetesGastrointestinalHospital ProductsIron & VitaminsPain ManagementRespiratory / AllergyUrology / Nephrology
Technology Platform
Advanced generic drug formulation and lyophilization manufacturing combined with a Jordan‑based R&D hub that develops best‑in‑class generic products and evaluates novel specialty therapies through licensing partnerships.
Opportunities
Expansion into specialty oncology and rare‑disease markets through licensing, plus continued growth of the generic portfolio across North Africa and the GCC.
Risk Factors
Regulatory delays, reliance on partner‑driven specialty pipelines, and intense competition from regional generic manufacturers.
Competitive Landscape
Competes with MENA generics leaders such as Hikma and Julphar; differentiation stems from its large manufacturing capacity, strategic specialty partnerships, and alignment with Saudi Vision 2030.